Related Experiment Video
Updated: Jul 4, 2026

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
Effect of domperidone on QT interval in neonates
Djamal Djeddi1, Guy Kongolo, Charlotte Lefaix
1Department of Pediatrics, School Hospital of Amiens, Amiens, France. djeddi.djamal-dine@chu-amiens.fr
Insights
Oral domperidone can prolong the corrected QT (QTc) interval in infants, particularly those with advanced gestational age and higher serum potassium levels. No ventricular arrhythmias were observed in this study.
Area of Science:
- Neonatal pharmacology
- Pediatric cardiology
- Clinical electrocardiology
Background:
- Domperidone is frequently used in neonates and infants.
- Potential cardiac side effects of domperidone require investigation.
Purpose of the Study:
- To assess the association between oral domperidone and QT interval prolongation in neonates and infants.
- To identify factors influencing domperidone-induced QTc changes.
- To evaluate the risk of ventricular arrhythmia with domperidone use.
Main Methods:
- Electrocardiogram (ECG) performed before and after oral domperidone administration.
- 31 neonates and infants were studied, categorized by gestational age.
- Analysis included univariate and multivariate assessments of influencing factors.
Main Results:
- Oral domperidone was associated with QTc prolongation (mean 14 msec) in infants with gestational age ≥ 32 weeks.
- Gestational age and serum potassium were identified as risk factors on univariate analysis.
- Serum potassium was the sole independent predictor of QTc prolongation on multivariate analysis.
- No ventricular arrhythmias were detected during the study.
Conclusions:
- Oral domperidone therapy is significantly associated with QTc prolongation in infants.
- Advanced gestational age and elevated serum potassium are key risk factors.
- Pre- and post-treatment QT interval measurements are recommended for infants receiving oral domperidone.
Objectives:
To determine whether oral domperidone is associated with QT interval prolongation and ventricular arrhythmia and to identify factors that can influence these effects.
Study Design:
An electrocardiogram was performed before and after oral administration of domperidone in 31 neonates or infants classified into 3 groups according to gestational age.
Results:
Oral domperidone is associated with QTc prolongation except in infants with a gestational age less than 32 weeks of amenorrhea (P < .005). Mean QTc prolongation was 14 msec. On univariate analysis, oral domperidone-induced QTc prolongation was correlated with gestational age, birth weight, and elevated serum potassium. On multivariate analysis, after adjustment for gestational age, serum potassium was the only factor independently associated with interval QT prolongation during treatment. No ventricular arrhythmias were observed.
Conclusions:
This study shows a significant association between oral domperidone therapy and QTc prolongation. Two risk factors were identified: advanced gestational age and serum potassium at the upper limit of normal. It is recommended that measurement of the QT interval be done before and after oral domperidone therapy.
Related Concept Videos
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Drug Dosing: Infants and Children
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Depolarizing Blockers: Pharmocokinetics
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
